A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

NCT06914037 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-cell Lymphoma
Cutaneous T-cell Lymphoma (CTCL)
NHL (Non-Hodgkin Lymphoma)

Interventions

DRUG: CHT101

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]